N,N′-ジ-9H-フルオレン-9-イル-N,N,N′,N′-テトラメチル-1,6-ヘキサンジアミニウム

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

CONSISTENT WITH ITS STABILIZING ACTION, IT POTENTIATES NEUROMUSCULAR BLOCKADE BY TUBOCURARINE & ANTAGONIZES THAT BY DECAMETHONIUM, BUT ITS EFFECTS ON BLOCKADE BY GALLAMINE ARE ERRATIC. PARADOXICALLY, IT MARKEDLY POTENTIATES & PROLONGS NEUROMUSCULAR ACTIONS OF SUCCINYLCHOLINE. /HEXAFLUORENIUM BROMIDE/

INTERACTION OF HEXAFLUORENIUM BROMIDE WITH ACETYLCHOLINE IODIDE, CARBACHOL & SUXAMETHONIUM CHLORIDE WITH REGARD TO DEPOLARIZATION OF THE END-PLATE OF RAT DIAPHRAGM WAS STUDIED.

POISONING FROM NEUROMUSCULAR BLOCKING AGENTS IS ALMOST ALWAYS RESULT OF CLINICAL OVERDOSAGE OR THEIR INJUDICIOUS USE. IMPORTANT UNTOWARD RESPONSES ARE PROLONGED APNEA, CARDIOVASCULAR COLLAPSE, & THOSE RESULTING FROM HISTAMINE RELEASE. /NEUROMUSCULAR BLOCKING AGENTS/

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

M - Musculo-skeletal system

QM - Musculo-skeletal system

Hexafluronium bromide is a cholinesterase antagonist that can be used to prolong the relaxation effects of succinylcholine or suxamethonium chloride. Suxamethonium acts as a depolarizing muscle relaxant. It imitates the action of acetylcholine at the neuromuscular junction and is degraded by pseudocholinesterase, a plasma cholinesterase. The prolonged stimulation of the acetylcholine receptor results first in disorganized muscle contractions, then in profound relaxation. Cholinesterases catalyze the hydrolysis of the neurotransmitter acetylcholine into choline and acetic acid, a reaction necessary to allow a cholinergic neuron to return to its resting state after activation. There are two types of cholinesterase acetylcholinesterase and pseuodocholinesterase. The first hydrolyses acetylcholine more quickly; the latter hydrolyses butyrylcholine and succinylcholine more quickly. An absence or mutation of the pseudocholinesterase enzyme leads to a medical condition known simply as pseudocholinesterase deficiency. This is a silent condition that only manifests itself when people who have the deficiency receive the muscle relaxants succinylcholine or mivacurium during a surgery.

Hexafluronium bromide is a non-competitive reversible inhibitor of human plasma cholinesterase or pseudocholinesterase. Hexafluornium probably binds to anionic side receptors near the active center, causing a conformational change in the enzyme, preventing acylation of the esteratic site. The esteratic site on cholistereases is where acetylcholine is hydrolyzed to acetic acid and choline.

... WORK ... HAS LED TO PROPOSAL THAT PREJUNCTIONAL MOTOR-NERVE TERMINAL IS PRIMARY SITE OF ACTION OF COMPETITIVE & DEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS. /NEUROMUSCULAR BLOCKING AGENTS/

...DESTRUCTION BY PLASMA CHOLINESTERASE IS...PRINCIPAL MEANS WHEREBY SUCCINYLCHOLINE IS DEGRADED, PROLONGATION OF ACTION MIGHT BE EXPLAINED BY ANTICHOLINESTERASE ACTION. HOWEVER, MARKED POTENTIATION CANNOT BE SO EXPLAINED, & VARIOUS EXPTL OBSERVATIONS INDICATE...INTERACTION @ NEUROMUSCULAR JUNCTION. /HEXAFLUORENIUM BROMIDE/